

Baxter International Inc.
Net Sales from Continuing Operations
Period Ending September 30, 2005
(unaudited)

(\$ in millions)	Q3 2005	Q3 2004	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2005	YTD 2004	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
United States	\$449	\$408	10%	10%	\$1,285	\$1,196	7%	7%
International	501	441	14%	12%	1,557	1,356	15%	10%
Total	\$950	\$849	12%	11%	\$2,842	\$2,552	11%	9%
Medication Delivery								
United States	\$531	\$593	(10%)	(10%)	\$1,702	\$1,716	(1%)	(1%)
International	426	393	8%	5%	1,316	1,202	9%	5%
Total	\$957	\$986	(3%)	(4%)	\$3,018	\$2,918	3%	1%
Renal								
United States	\$96	\$101	(5%)	(5%)	\$289	\$303	(5%)	(5%)
International	395	384	3%	-%	1,209	1,135	7%	2%
Total	\$491	\$485	1%	(1%)	\$1,498	\$1,438	4%	-%
Baxter International Inc.								
United States	\$1,076	\$1,102	(2%)	(2%)	\$3,276	\$3,215	2%	2%
International	1,322	1,218	9%	6%	4,082	3,693	11%	6%
Total	\$2,398	\$2,320	3%	2%	\$7,358	\$6,908	7%	4%